Well, for all the moaning about the Fed being the grinch by not giving the market a nice shiny interest rate drop, the NASDAQ Composite was in the red, but not a huge amount, -0.5% for the week, leaving its YTD performance a strong return of +7.8%. The biotech indices were weaker, shaving off roughly -2% of value in one week, and ending with YTD performances in the red (-1.3% for the S&P biotechs, and -4% for the NASDAQ biotech composite).
For individual stocks the big winner was VERU up +83% of its price at the beginning of the year, and making it into fifth place for YTD performance, +110% . No news on Yahoo for the last week. Some weeks back they rescheduled their stockholders meeting based on having to release revised financials, that supposedly gives them more cash on hand. But why wait until this week for the price to makes its move? It is a mystery.
Second place LPTX (+17%) announced a $40M private placement. Fifth place for the week TMDX (+8.4%) was a subject of a technical analysis report released on Thursday, in part because of its products used in organ transplant and end-stage organ failure.
And speaking of failure, the week’s big losers include a few familiar high flyers. In fact other than the entry of VERU, every one of the stocks in the top five YTD list suffered a lost this week, some quite significant.
For example, this weeks worst performer was VINC (-390% of its original price). This dislodged VINC from their first place spot in the YTD performance and in fact is a net loss for the year at this point; They had a press release after Monday’s market close whose title began: “Vincerx Pharma Presents Positive Preliminary Phase 1 Data”. Then when the market opened on Tuesday it promptly plunged from $4.78 / share to $1.48. Apparently “Positive Data” wasn’t positive enough, as some analysts termed the results as “disappointing”.
TCON executed a twenty for one referee stock spli, announced Monday and effective Tuesdayt, and even after correcting for this they were the second worst performer for the week (-81%). CDTX (-44%) also had “positive results” released last Friday,
The indomitable vikings at VKTX lost -42% this week, (but still in second place YTD, +270%). Because of its trendy therapeutic weight loss potential products, it has continued to attract a lot of analyst attention: three articles from Motley Fool were over all negative, while other analysts opined that a buy might not be amiss.
I think we might predict then that the portfolios did not fare particularly well. The week handed a $8.4k loss to the average portfolio, the YTD Avg (+$12.9$k is still outpacing the NASDAQ Composite, if not the median portfolio ( +$6.3k). Only one portfolio managed to turn a profit this week, KATHLEEN, the only contestant with a position in VERU, which added $8.3k for the week. Alas, the losses from their other holdings meant that net change for the week was barely in the black, +$420.
The YTD portfolio standings show a little movement. BLADERUNNER is still in first, though dropping below they previous gain over +$100k, to +$95k, with BULBAMAN still in second (+$56k) with a very slight widening of the gap between them. AT 3rd and 4th, ERIKOTTO rose to displace RAJU_BIJLEE. DEW_DILIGENCE turned in an above average performance for the week, in 7th place, which allowed him to jump from 8th to 5th YTD (+$17k).
Report Time Ranges
|
|
|
|
|
|
From
|
To
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Recent
|
4/5/2024
|
4/12/2024
|
|
|
|
|
|
|
|
|
YTD
|
12/31/2023
|
|
|
|
|
Index Portfolios’ Performance
|
|
|
|
|
Symbol
|
Recent P/L
|
Recent %
|
YTD P/L
|
|
|
|
|
|
|
|
|
^IXIC
|
-$489.14
|
-0.5%
|
$7,752.41
|
|
|
|
|
|
|
|
|
^NBI
|
-$1,874.02
|
-1.9%
|
-$4,014.47
|
|
|
|
|
|
|
|
|
^SPSIBI
|
-$2,365.18
|
-2.3%
|
-$1,307.04
|
|
|
|
|
Share Performance
|
Recent Performance
|
YTD Performance
|
|
Top Five
|
|
Bottom Five
|
|
Top Five
|
|
Bottom 5
|
Symbol
|
P/L / Initial Price
|
Symbol
|
P/L / Initial Price
|
Symbol
|
YTD P/L / Initial Price
|
Symbol
|
YTD P/L/ Initial Price
|
VERU
|
82.6%
|
VINC
|
-387.3%
|
CRDF
|
279.1%
|
AMLX
|
-85.7%
|
LPTX
|
16.9%
|
TCON
|
-81.1%
|
VKTX
|
268.7%
|
CNSP
|
-80.8%
|
IMUX
|
10.7%
|
CDTX
|
-44.1%
|
JSPR
|
251.3%
|
EYEN
|
-74.5%
|
URGN
|
10.0%
|
VKTX
|
-42.1%
|
PYXS
|
173.3%
|
PACB
|
-67.7%
|
TMDX
|
8.4%
|
TARA
|
-33.6%
|
VERU
|
111.1%
|
NERV
|
-59.3%
|
Average and Median Portfolio Performance
|
|
Recent P/L
|
|
|
|
YTD P/L
|
|
|
|
Avg.
|
Median
|
|
|
|
Avg
|
Median
|
|
|
|
-$8,396.49
|
-$6,018.35
|
ARTHUR RADLEY
|
|
$12,909.01
|
$6,254.88
|
JACK HARTMANN
|
Top Seven Portfolio Performances
|
Top Recent Performers
|
Top YTD Performers
|
Contestant (Prev. Rank)
|
Recent P/L
|
P/L vs. ^SPSIBI
|
YTD P/L (Rank)
|
Contestant (Prev. Rank)
|
YTD P/L
|
vs. Top Portfolio
|
P/L vs. ^SPSIBI
|
Rec. P/L (Rank)
|
1 - KATHLEEN (8)
|
$424.57
|
$2,789.75
|
$1,166.53 (10)
|
1 - BLADERUNNER (1)
|
$95,071.93
|
——
|
$96,378.97
|
-$15,193.78 (15)
|
2 - A. J. MULLEN (5)
|
-$1,190.57
|
$1,174.62
|
-$23,290.76 (17)
|
2 - BULBAMAN (2)
|
$55,963.35
|
$39,108.58
|
$57,270.39
|
-$16,639.09 (16)
|
3 - JACK HARTMANN (9)
|
-$2,263.78
|
$101.40
|
$6,254.88 (9)
|
3 - ERIKOTTO (4)
|
$34,327.04
|
$60,744.89
|
$35,634.08
|
-$8,087.82 (10)
|
4 - NOTABOT (10)
|
-$2,523.30
|
-$158.12
|
-$10,296.83 (15)
|
4 - RAJU_BIJLEE (3)
|
$34,263.75
|
$60,808.18
|
$35,570.79
|
-$11,724.48 (12)
|
5 - STEVE LOKNESS (11)
|
-$3,201.24
|
-$836.05
|
-$811.55 (11)
|
5 - DEW_DILIGENCE (8)
|
$17,343.26
|
$77,728.66
|
$18,650.31
|
-$4,548.89 (7)
|
6 - DART LANZER (4)
|
-$3,486.89
|
-$1,121.71
|
-$5,671.39 (13)
|
6 - TRACE I11 (5)
|
$12,517.55
|
$82,554.38
|
$13,824.59
|
-$24,065.98 (17)
|
7 - DEW_DILIGENCE (14)
|
-$4,548.89
|
-$2,183.71
|
$17,343.26 (5)
|
7 - TECHNETIUM (7)
|
$12,203.42
|
$82,868.51
|
$13,510.46
|
-$9,847.45 (11)
|
8 - JR_95 (12)
|
-$5,136.09
|
-$2,770.91
|
-$2,379.86 (12)
|
8 - TOMATO (6)
|
$11,441.60
|
$83,630.33
|
$12,748.64
|
-$14,968.02 (14)
|
Top Portfolios’ Contents
|
Top Recent Performance Portfolio (KATHLEEN)
|
Top YTD Performance Portfolio (BLADERUNNER)
|
Symbol (Rank)
|
Initial Allocation
|
Value/Total | ROI
|
YTD Stock P/L
|
Recent Stock P/L
|
% Current Price Change for $1,000 P/L
|
Symbol (Rank)
|
Initial Allocation
|
Value/Total | ROI
|
YTD Stock P/L
|
Recent Stock P/L
|
% Current Price Change for $1,000 P/L
|
CNSP
|
10.00%
|
1.9% | -80.8%
|
-$8,083.46
|
-$118.90
|
52.2%
|
BCAB
|
10.00%
|
6.5% | 27.2%
|
$2,723.58
|
-$2,723.58
|
7.9%
|
CRVS
|
10.00%
|
8.6% | -13.1%
|
-$1,306.82
|
-$1,250.00
|
11.5%
|
CRDF
|
20.00%
|
38.9% | 279.1%
|
$55,810.81
|
-$3,108.11
|
1.3%
|
ITRM
|
10.00%
|
7.9% | -19.8%
|
-$1,979.70
|
-$913.71
|
12.5%
|
CRIS
|
10.00%
|
6.1% | 19.8%
|
$1,984.31
|
-$1,192.16
|
8.3%
|
LXRX
|
10.00%
|
12.7% | 28.8%
|
$2,875.82
|
-$588.24
|
7.8%
|
GLYC
|
10.00%
|
5.2% | 1.7%
|
$169.49
|
-$1,483.05
|
9.8%
|
ONVO
|
10.00%
|
9.0% | -9.0%
|
-$900.00
|
-$89.19
|
11.0%
|
IMMP
|
10.00%
|
5.3% | 3.8%
|
$375.00
|
-$1,291.67
|
9.6%
|
PSTV
|
10.00%
|
10.5% | 6.3%
|
$628.57
|
-$114.29
|
9.4%
|
IOVA
|
20.00%
|
15.6% | 52.0%
|
$10,405.90
|
-$2,878.23
|
3.3%
|
SCYX
|
10.00%
|
6.4% | -35.2%
|
-$3,520.18
|
-$1,188.34
|
15.4%
|
JSPR
|
10.00%
|
18.0% | 251.3%
|
$25,133.08
|
-$2,256.02
|
2.8%
|
SLDB
|
10.00%
|
16.7% | 68.9%
|
$6,889.25
|
-$2,915.31
|
5.9%
|
REPL
|
10.00%
|
4.3% | -15.3%
|
-$1,530.25
|
-$260.97
|
11.8%
|
VERU
|
10.00%
|
20.9% | 111.1%
|
$11,111.11
|
$8,262.50
|
4.7%
|
|
|
|
|
|
|
VERV
|
10.00%
|
5.4% | -45.5%
|
-$4,548.06
|
-$659.97
|
18.3%
|
|
|
|
|
|
|
|
